People · Operator
Named in public records as an officer, director or promoter · active 2013–2013 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Omni Bio Pharmaceutical, Inc. | — | Pharmaceuticals | Series B | $29.8M | $52.4M | 2013 |
Bruce Schneider at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Bruce Schneider on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| BRIAN KLEMSZ | 1 | 4 |
| ROBERT OGDEN | 1 | 2 |
| Vicki Barone | 1 | 2 |
| JEFFREY SPERBER | 1 | 2 |
| Steven Bathgate | 1 | 2 |
| Michael Iseman | 1 | 2 |
| Michael Kamarck | 1 | 2 |
| JAMES CRAPO | 1 | 2 |
| Michael Wort | 1 | 1 |
| Albert Kramer | 1 | 1 |
| Edward Larkin | 1 | 1 |
| Charles Dinarello | 1 | 1 |
| Ed Larkin | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.